Alpha Beta T-cell and B-cell depleted allogeneic transplantation followed by Blinatumomab therapy for high-risk B-Acute Lymphoblastic Leukemia pilot study

Children’s Wisconsin is currently enrolling on this pilot study. This trial will assess the feasibility of alpha/beta T-cell and B-cell depleted allogeneic hematopoietic cell transplantation (HCT) followed by Blinatumomab therapy for high-risk B cell Acute Lymphoblastic Leukemia (ALL) as a means of reducing rates of subsequent relapse and improving survival, while also minimizing treatment-related morbidity/ mortality and late effects. The conditioning regimens will be dependent on the patient's minimal residual disease (MRD) status prior to HCT using high throughput sequencing. This multi-institutional study will be limited to 25 (estimated 10-15 per stratum) evaluable children, adolescents and young adults with B-ALL, that have experienced a relapse or have high-risk disease. Patients must be enrolled on our phase 2 Blinatumomab bridging study in order to be eligible for this study.

ClinicalTrials.gov identifier (NCT number): NCT04746209

Investigator and Study Chair: Rachel Phelan, MD, MPH

For more information contact: Tara Murphy | Clinical Research RN | 414-266-6471